Literature DB >> 26802533

Myasthenia gravis exacerbation associated with pembrolizumab.

Julia Zhu1, Yuebing Li1.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 26802533     DOI: 10.1002/mus.25055

Source DB:  PubMed          Journal:  Muscle Nerve        ISSN: 0148-639X            Impact factor:   3.217


× No keyword cloud information.
  13 in total

1.  Ipilimumab treatment associated with myasthenic crises and unfavorable disease course.

Authors:  Eda Derle; Sibel Benli
Journal:  Neurol Sci       Date:  2018-06-13       Impact factor: 3.307

Review 2.  Neurological Complications of Therapeutic Monoclonal Antibodies: Trends from Oncology to Rheumatology.

Authors:  Chandler Gill; Stasia Rouse; Ryan D Jacobson
Journal:  Curr Neurol Neurosci Rep       Date:  2017-08-17       Impact factor: 5.081

Review 3.  Neurotoxicity and safety of the rechallenge of immune checkpoint inhibitors: a growing issue in neuro-oncology practice.

Authors:  M Villagrán-García; R Velasco
Journal:  Neurol Sci       Date:  2022-02-17       Impact factor: 3.830

Review 4.  Neurological Adverse Events Associated with Immune Checkpoint Inhibitors: Diagnosis and Management.

Authors:  Christophoros Astaras; Rita de Micheli; Bianca Moura; Thomas Hundsberger; Andreas F Hottinger
Journal:  Curr Neurol Neurosci Rep       Date:  2018-02-01       Impact factor: 5.081

Review 5.  Neuromuscular Complications of Programmed Cell Death-1 (PD-1) Inhibitors.

Authors:  Justin C Kao; Adipong Brickshawana; Teerin Liewluck
Journal:  Curr Neurol Neurosci Rep       Date:  2018-08-04       Impact factor: 5.081

6.  Emergence of Myasthenia Gravis with Myositis in a Patient Treated with Pembrolizumab for Thymic Cancer.

Authors:  So Young Huh; Seong Hoon Shin; Meyung Kug Kim; So Young Lee; Ki Hun Son; Ha Young Shin
Journal:  J Clin Neurol       Date:  2018-01       Impact factor: 3.077

7.  Pembrolizumab-induced myasthenia gravis with myositis in a patient with lung cancer.

Authors:  Makoto Hibino; Kazunari Maeda; Shigeto Horiuchi; Minoru Fukuda; Tetsuri Kondo
Journal:  Respirol Case Rep       Date:  2018-08-07

Review 8.  Efficacy and Toxicity of Immune -Checkpoint Inhibitors in Patients With Preexisting Autoimmune Disorders.

Authors:  Michelle Coureau; Anne-Pascale Meert; Thierry Berghmans; Bogdan Grigoriu
Journal:  Front Med (Lausanne)       Date:  2020-05-07

9.  Pembrolizumab treatment of metastatic urothelial cancer without exacerbating myasthenia gravis.

Authors:  Akiko Ishii; Minato Yokoyama; Hiroshi Tsuji; Yasuhisa Fujii; Akira Tamaoka
Journal:  eNeurologicalSci       Date:  2020-03-14

Review 10.  Immune-Driven Pathogenesis of Neurotoxicity after Exposure of Cancer Patients to Immune Checkpoint Inhibitors.

Authors:  Noelia Vilariño; Jordi Bruna; Foteini Kalofonou; Garifallia G Anastopoulou; Andreas A Argyriou
Journal:  Int J Mol Sci       Date:  2020-08-11       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.